What’s New With HER2: Charting New Paths in NSCLC Care - Module 1: HER2 in NSCLC: Actionable Insights and Testing Recommendations

STATEMENT OF NEED

With the identification of oncogenic drivers and the development of targeted therapies, comprehensive molecular assessment has become a cornerstone of non"small cell lung cancer (NSCLC) management. Human epidermal growth factor receptor 2 (HER2) alterations, which include gene mutations, gene amplifications, and protein overexpression, are emerging therapeutic targets. While testing can be used to guide treatment decisions, the heterogeneity of HER2 alterations and their differing implications for targeted therapy can pose challenges (Uy et al, 2022). Therefore, it is crucial for clinicians to remain up to date on emerging biomarker testing guidelines and methodologies in order to plan optimal treatment strategies for their patients. In Module 1 of this activity, Dr. Julia Kathleen Rotow, Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, will explore actionable insights and testing recommendations for HER2 alterations in NSCLC.

TARGET AUDIENCE

Oncologists, pulmonologists, oncology nurses, advanced practice providers, and other health care professionals involved in the treatment of patients with non"small cell lung cancer (NSCLC).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to

Discuss the significance of HER2 mutations in NSCLC and their implications for treatment planning
Identify methods for detecting HER2 mutations in NSCLC and adherence to biomarker testing guidelines